Compounds > 5,8-dihydroxy-3-methyl-4-(9h)-naphtho(2,3-c)furanone
Page last updated: 2024-11-07

5,8-dihydroxy-3-methyl-4-(9h)-naphtho(2,3-c)furanone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

5,8-dihydroxy-3-methyl-4-(9H)-naphtho(2,3-c)furanone: isolated from Micromonospora sp. KY7123; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID132904
CHEMBL ID1240928
SCHEMBL ID22893409
MeSH IDM0254166

Synonyms (21)

Synonym
150045-18-4
ms-444
5,8-dihydroxy-3-methyl-4-(9h)-naphtho(2,3-c)furanone
ms 444
5,8-dihydroxy-3-methyl-9h-naphtho[2,3-c]furan-4-one
5,8-dihydroxy-3-methyl-9h-benzo[f][2]benzofuran-4-one
CHEMBL1240928 ,
5,8-dihydroxy-3-methylnaphtho[2,3-c]furan-4(9h)-one
bdbm50326009
AC-33656
DTXSID40164458
HY-100685
CS-0019951
AKOS032946366
BCP25098
5,8-dihydroxy-3-methyl-naphtho[2,3-c]furan-4(9h)-one
be-34776
MS-23304
SCHEMBL22893409
naphtho[2,3-c]furan-4(9h)-one, 5,8-dihydroxy-3-methyl-
5,8-dihydroxy-3-methyl-4h,9h-naphtho[2,3-c]furan-4-one
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Myosin light chain kinase, smooth muscleHomo sapiens (human)IC50 (µMol)10.00000.02202.413310.0000AID507020
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ELAV-like protein 1Homo sapiens (human)Kd0.13280.00010.13280.4200AID506988; AID506989; AID507002; AID507003; AID507006
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (19)

Processvia Protein(s)Taxonomy
positive regulation of translationELAV-like protein 1Homo sapiens (human)
mRNA stabilizationELAV-like protein 1Homo sapiens (human)
protein import into nucleusELAV-like protein 1Homo sapiens (human)
post-transcriptional gene silencingELAV-like protein 1Homo sapiens (human)
positive regulation of superoxide anion generationELAV-like protein 1Homo sapiens (human)
mRNA stabilizationELAV-like protein 1Homo sapiens (human)
protein homooligomerizationELAV-like protein 1Homo sapiens (human)
negative regulation of miRNA-mediated gene silencingELAV-like protein 1Homo sapiens (human)
mRNA destabilizationELAV-like protein 1Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationELAV-like protein 1Homo sapiens (human)
regulation of stem cell population maintenanceELAV-like protein 1Homo sapiens (human)
protein phosphorylationMyosin light chain kinase, smooth muscleHomo sapiens (human)
smooth muscle contractionMyosin light chain kinase, smooth muscleHomo sapiens (human)
tonic smooth muscle contractionMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of cell migrationMyosin light chain kinase, smooth muscleHomo sapiens (human)
bleb assemblyMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of calcium ion transportMyosin light chain kinase, smooth muscleHomo sapiens (human)
aorta smooth muscle tissue morphogenesisMyosin light chain kinase, smooth muscleHomo sapiens (human)
cellular hypotonic responseMyosin light chain kinase, smooth muscleHomo sapiens (human)
positive regulation of wound healingMyosin light chain kinase, smooth muscleHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
RNA bindingELAV-like protein 1Homo sapiens (human)
double-stranded RNA bindingELAV-like protein 1Homo sapiens (human)
mRNA bindingELAV-like protein 1Homo sapiens (human)
mRNA 3'-UTR bindingELAV-like protein 1Homo sapiens (human)
protein bindingELAV-like protein 1Homo sapiens (human)
protein kinase bindingELAV-like protein 1Homo sapiens (human)
miRNA bindingELAV-like protein 1Homo sapiens (human)
mRNA 3'-UTR AU-rich region bindingELAV-like protein 1Homo sapiens (human)
protein homodimerization activityELAV-like protein 1Homo sapiens (human)
lncRNA bindingELAV-like protein 1Homo sapiens (human)
actin bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
myosin light chain kinase activityMyosin light chain kinase, smooth muscleHomo sapiens (human)
protein bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
calmodulin bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
ATP bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
metal ion bindingMyosin light chain kinase, smooth muscleHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (18)

Processvia Protein(s)Taxonomy
P-bodyELAV-like protein 1Homo sapiens (human)
nucleusELAV-like protein 1Homo sapiens (human)
nucleoplasmELAV-like protein 1Homo sapiens (human)
cytoplasmELAV-like protein 1Homo sapiens (human)
endoplasmic reticulumELAV-like protein 1Homo sapiens (human)
cytosolELAV-like protein 1Homo sapiens (human)
cytoplasmic stress granuleELAV-like protein 1Homo sapiens (human)
membraneELAV-like protein 1Homo sapiens (human)
sarcoplasmELAV-like protein 1Homo sapiens (human)
cytoplasmic vesicleELAV-like protein 1Homo sapiens (human)
postsynapseELAV-like protein 1Homo sapiens (human)
glutamatergic synapseELAV-like protein 1Homo sapiens (human)
ribonucleoprotein complexELAV-like protein 1Homo sapiens (human)
stress fiberMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytosolMyosin light chain kinase, smooth muscleHomo sapiens (human)
plasma membraneMyosin light chain kinase, smooth muscleHomo sapiens (human)
actin cytoskeletonMyosin light chain kinase, smooth muscleHomo sapiens (human)
lamellipodiumMyosin light chain kinase, smooth muscleHomo sapiens (human)
cleavage furrowMyosin light chain kinase, smooth muscleHomo sapiens (human)
cleavage furrowMyosin light chain kinase, smooth muscleHomo sapiens (human)
stress fiberMyosin light chain kinase, smooth muscleHomo sapiens (human)
lamellipodiumMyosin light chain kinase, smooth muscleHomo sapiens (human)
cytoplasmMyosin light chain kinase, smooth muscleHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID507001Inhibition of IL-6 gene expression in LPS/INF-gamma-stimulated human primary monocytes by RT-PCR analysis2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID507014Inhibition of IL1-beta expression in LPS/INF-gamma-stimulated human primary monocytes by ELISA2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID507009Inhibition of HuR homodimerization by size-exclusion chromatography in presence of low UV irradiation2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID507000Inhibition of COX-2 gene expression in LPS/INF-gamma-stimulated human primary monocytes by RT-PCR analysis2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID506999Inhibition of IL1-beta gene expression in LPS/INF-gamma-stimulated human primary monocytes by RT-PCR analysis2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID506993Inhibition of recombinant full length HuR assessed as inhibition of protein-IL-2 A/U-rich element interaction-associated release of particle number at 2 uM by 2D-FIDA2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID506995Inhibition of HuR in anti-CD3 and anti-CD28-stimulated human PBMC assessed as reduction of cytoplasmic protein level at 25 uM after 48 hrs by confocal microscopy2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID507010Inhibition of HuR homodimerization by Western blot analysis2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID506994Binding affinity to HuR after 24 hrs by microdialysis method2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID506992Inhibition of HuR homodimerization after 24 hrs by microdialysis in presence of low UV irradiation2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID506989Inhibition of recombinant HuR RRM1/RRM2 domain assessed as protein interaction with TMR-labeled A/U-rich element of TNFalpha by confocal fluctuation spectroscopy2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID507002Inhibition of recombinant HuR RRM1/RRM2 domain assessed as protein dimerization with TMR-labeled A/U-rich element of TNFalpha by confocal fluctuation spectroscopy2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID507015Inhibition of COX-2 expression in LPS/INF-gamma-stimulated human primary monocytes by ELISA2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID507006Binding affinity recombinant HuR RRM1/RRM2 domain by confocal fluctuation spectroscopy2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID507003Inhibition of recombinant HuR RRM1/RRM2 domain assessed as protein dimerization with TMR-labeled A/U-rich element of IL-2 by confocal fluctuation spectroscopy2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID507020Inhibition of MYLK2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID506988Inhibition of recombinant HuR RRM1/RRM2 domain assessed as protein interaction with TMR-labeled A/U-rich element of IL-2 by confocal fluctuation spectroscopy2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID506998Cytotoxicity against human PBMC assessed as cell viability at 25 uM after 48 hrs relative control2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
AID507016Inhibition of IL-6 expression in LPS/INF-gamma-stimulated human primary monocytes by ELISA2007Nature chemical biology, Aug, Volume: 3, Issue:8
Identification and mechanistic characterization of low-molecular-weight inhibitors for HuR.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (27.27)18.2507
2000's1 (9.09)29.6817
2010's4 (36.36)24.3611
2020's3 (27.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.67 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.15 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2-naphthol
2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.		3.6690naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
ConditionIndicatedRelationship StrengthStudiesTrials
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.610
Cancer of Lung
[description not available]		02.610
Lung Neoplasms
Tumors or cancer of the LUNG.		02.610
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.610
Benign Neoplasms
[description not available]		02.3110
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.3110
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		02.5420
Adenomatous Polyposis Coli, Familial
[description not available]		02.1510
Colorectal Cancer
[description not available]		02.5420
Bowel Diseases, Inflammatory
[description not available]		02.1510
Adenomatous Polyposis Coli
A polyposis syndrome due to an autosomal dominant mutation of the APC genes (GENES, APC) on CHROMOSOME 5. The syndrome is characterized by the development of hundreds of ADENOMATOUS POLYPS in the COLON and RECTUM of affected individuals by early adulthood.		02.1510
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		02.5420
Inflammatory Bowel Diseases
Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS.		02.1510
Glial Cell Tumors
[description not available]		02.2110
Glioma
Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)		02.2110
Malignant Melanoma
[description not available]		02.1310
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.1310